Diagnostic Imaging November 21, 2023
Jeff Hall

Pixyl.Neuro reportedly leverages generative artificial intelligence (AI) technology to accelerate brain MRI assessment and improve early detection of abnormal atrophy.

The Food and Drug Administration (FDA) has granted 510(k) clearance for Pixyl.Neuro™, an adjunctive artificial intelligence (AI)-powered software that may enhance magnetic resonance imaging (MRI) detection and follow-up of patients with neurological disorders including Alzheimer’s disease and multiple sclerosis (MS).

Reportedly providing automated brain MRI analysis in less than five minutes, Pixyl.Neuro may help quantify brain region volume to aid in the differential diagnosis and facilitate earlier identification of atrophy, according to Pixyl, the developer of the software.

Lotfi Hacein-Bey, M.D, said...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

Continue Reading

 
Topics: AI (Artificial Intelligence), FDA, Govt Agencies, Provider, Radiology, Technology
Related Articles:
90% of Healthcare C-Suite Sees Positive Return From GenAI
The Future of Residency: Is AI Reshaping the Match?
AI Investments Expected to Shift to Inference While Growing Faster Than Forecast
Report: OpenAI to Test Feature Connecting ChatGPT to Slack and Google Drive
Vaccines And AI

Share This Article